8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 24, 2009

Merck & Co., Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

New Jersey	1-3305	22-1109110
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)
One Merck Drive, P.O. Box 100, Whitehouse Station, New Jersey		08889
_________________________________ (Address of principal executive offices)		___________ (Zip Code)

Registrant’s telephone number, including area code: 908-423-1000

Not Applicable
______________________________________________
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) Incorporated by reference is a press release issued by Merck & Co., Inc. (the "Company") on February 17, 2009, attached as Exhibit 99.1, announcing the election of Carlos E. Represas to the Company's Board of Directors, effective February 24, 2009. Board Committee assignments for Mr. Represas will be determined at a later date.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit 99.1 Press Release issued February 17, 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Merck & Co., Inc.
February 24, 2009	By:	/s/ Debra A. Bollwage
		Name: Debra A. Bollwage
		Title: Senior Assistant Secretary

Exhibit Index

Exhibit No.	Description
99.1	Press release issued February 17, 2009

EX-99.1

Exhibit 99.1

News Release

Media Contact: Amy Rose
(908) 423-6537 Investor Contact: Eva Boratto
(908) 423-5185

Carlos E. Represas Elected to Merck Board of Directors

WHITEHOUSE STATION, N.J., Feb. 17, 2009 – Merck & Co., Inc. today announced that Carlos E. Represas, 63, chairman of Nestlé Mexico, will join the Company’s board of directors effective Feb. 24. With his election, Mr. Represas will become one of 13 outside directors on the 14-member board. Mr. Represas will stand for election by the Company’s stockholders in April 2009.

“Carlos has a broad range of global business experience that will be invaluable to Merck,” said Richard T. Clark, chairman, president, and chief executive officer. “We look forward to his insights and perspectives, and we welcome him to the board.”

In 2004, Mr. Represas retired as executive vice president and head of the Americas for Nestlé S.A. Prior to serving in that role, he held positions of increasing responsibility during his 36 years at the company, including the position of chairman, president and CEO of Nestle Group Mexico from 1983 to 1994.

Mr. Represas is a member of the Latin American Business Council and the boards of the Mexican Health Foundation and the Latin American Chamber of Commerce in Switzerland. Additionally, he is the chairman of the Board of Trustees of Mexico’s National Institute of Genomic Medicine. He also serves on the corporate board of Bombardier Inc., Canada.

Mr. Represas earned a bachelor’s degree in economics from the National University of Mexico. He has been decorated by different South American countries and received Doctor Honoris Causa degrees from the Federal University of Vicosa in Brazil in 1998 and from the Mexican Academy of International Law in 2001.

Separately, Merck announced last week that Dr. Johnnetta B. Cole resigned from the Board of Directors, effective March 1, to become Director of the Smithsonian’s National Museum of African Art.

About Merck

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.

# # #